MP Materials

Phase A — Understand the business

Lens 1 · Company Overview

MP Materials is the largest producer of rare-earth materials in the Western Hemisphere. It owns and operates the Mountain Pass mine and processing facility in San Bernardino County, California — the only rare-earth mining-and-processing site of scale in North America — and the Independence Facility in Fort Worth, Texas (~18 acres), a rare-earth metal, alloy and magnet plant that anchors the downstream Magnetics segment. HQ: Las Vegas, Nevada. Incorporated in Delaware; NYSE: MP.

The business model is in the middle of a deliberate transformation from a mine-and-ship concentrate seller into a vertically-integrated "mine-to-magnet" producer. Historically MP dug ore at Mountain Pass, roasted it into rare-earth concentrate, and sold that concentrate — predominantly to China for separation — under offtake agreements with Shenghe Resources (a Chinese rare-earth firm that is also one of MP's largest shareholders). The strategy now is to keep the entire value chain onshore: separate the concentrate into refined NdPr oxide and metal at Mountain Pass, then turn that into NdFeB magnetic precursor and finished magnets at Independence.

Two reporting segments:

• Materials — Mountain Pass mining, concentrate, and refined NdPr oxide/metal.
• Magnetics — Independence Facility precursor + finished NdFeB magnets.

Revenue lines (Q1'26): NdPr oxide and metal $71.1M; Magnetic precursor products $21.1M; Rare earth concentrate $0; Other $1.0M; intersegment elim $(2.6)M → total $90.6M. The disappearance of the concentrate line is the whole story — see Lens 4.

Key customers / counterparties:

• U.S. Department of Defense — since July 9, 2025, MP's anchor customer, largest shareholder, and price backstop (see Lens 3).
• General Motors — long-term magnet supply agreement (2022); takes finished NdFeB from Independence; prepaid $100M (2024) + $50M (Apr 2025); initial allocation ~1,000 tons.
• Sumitomo Corporation of Americas — distribution agreement for NdPr oxide/metal.
• A "leading U.S. technology and industrial company" — new NdPr offtake signed Q1'26 (widely reported as Apple).
• Shenghe Resources — the now-severed concentrate offtake counterparty; remains a top equity holder.

Contract structure: a mix of (a) market-priced concentrate (now zero), (b) NdPr sold under distribution/offtake at prevailing prices, (c) the GM magnet supply agreement with prepayments, and crucially (d) the DoD Price Protection Agreement that pays MP the shortfall between a $110/kg NdPr floor and the realized benchmark price — i.e. a quasi take-or-pay on price, not volume.

Lens 2 · Supply Chain

Upstream → MP → end customer, named at every node:

Upstream inputs. Mountain Pass is a hard-rock bastnäsite open-pit mine; the orebody's TREO distribution is Cerium 50.2% / Lanthanum 32.3% / NdPr 15.7% / SEG+ 1.8%. The economically critical fraction is the ~15.7% NdPr. MP is largely self-sufficient on feedstock — it mines its own ore — which is the defining supply-chain advantage versus separation-only or magnet-only peers who must buy feed. Consumables (reagents, natural gas for the combined-heat-and-power plant, HCl) are the main purchased inputs.

The chokepoint MP is attacking: separation and metallization. China controls ~85–90% of global rare-earth separation and the vast majority of magnet-making. Historically MP itself was part of that chokepoint dependency — it shipped concentrate to Shenghe → China for separation. The entire capital program (Stage II separation at Mountain Pass, Independence metal/magnet, the future 10X facility) is about removing China from its own value chain.

Midstream (MP's own assets).

• Mountain Pass: mine + roasting (concentrate) + Stage II separation (NdPr oxide) + Stage III metal.
• Independence (Fort Worth): NdPr metal → NdFeB alloy/strip → sintered finished magnets. Capacity ~1,000 MT/yr finished magnets; first commercial NdFeB magnets produced December 2025.
• 10X Facility (under development): second, far larger magnet plant; commissioning targeted 2028; lifts total magnet capacity to ~10,000 MT/yr.

Downstream / end customers. DoD (defense + commercial magnets, 7,000 MT/yr offtake for 10 yrs), GM (auto traction motors), Sumitomo (NdPr distribution), the unnamed tech/industrial offtaker (reported Apple), and merchant NdPr buyers.

Single-source / dependency flags:

• Customer concentration was extreme and is being re-pointed. Shenghe was ~80% of consolidated revenue (9M 2024) → ~30% (9M 2025, mostly concentrate) → 0 going forward. MP swapped Chinese-customer concentration for U.S.-government concentration (DoD as anchor buyer + backstop + 15% owner). Different counterparty, still concentrated.
• Heavy-rare-earth (Dy/Tb) gap. Mountain Pass is NdPr-rich but light on the heavy rare earths needed for high-temperature magnets; the 10-K flags heavy-REE ramp as a parallel objective. This is the one input MP does not yet fully control.

Lens 3 · Competitive Advantages (moats)

1. The asset itself — irreplaceable scale. Mountain Pass is the rare-earth mine of scale in the Western Hemisphere; there is no second comparable Western orebody in production. Permitting + building a new one is a decade-plus undertaking. This is a genuine, durable, geology-based moat. Bargaining power over Western customers who must de-risk China is high.
2. The DoD price floor — a structural, contractual moat unique in the sector. The July 2025 Price Protection Agreement guarantees $110/kg NdPr for 10 years, with DoD paying the quarterly shortfall versus the benchmark price. No competitor has this. It removes commodity-price risk from the downside — the single thing that has historically killed rare-earth miners (China floods the market, prices collapse, the Western producer dies; this is literally how MP's predecessor Molycorp went bankrupt). MP's floor is well above where NdPr has traded recently, so it is real money, not a theoretical backstop ($51.0M of price-protection income recognized in FY2025; $42.3M in Q1'26 alone).
3. Government as anchor customer + 15% owner — aligned, deep-pocketed sponsor. DoD's $400M preferred + warrant and 7,000 MT/yr, 10-yr offtake make the U.S. government structurally invested in MP's success. This is closer to a national champion than a normal commercial relationship.
4. First-mover, vertical integration. MP is years ahead of every other Western magnet aspirant (USA Rare Earth, Energy Fuels, Vulcan) in actually producing refined NdPr and commercial magnets at scale. Switching costs build as OEMs (GM, defense primes) qualify MP's magnets into multi-year programs — magnet qualification is slow and sticky.

Bargaining power. Over Western customers: high (few alternatives, policy tailwind). Over the global market clearing price: low — China still sets the NdPr price, which is exactly why the DoD floor matters. Over suppliers: high (self-mined feed). The honest read: MP's moat on the downside is policy/contract; its moat on the upside is the asset.

Lens 4 · Segments

Segment economics and the mix shift (all ``):

FY2025 (full year):

Revenue by product line — the inflection (Q1'26 vs Q1'25):

The story in one line: MP deliberately took the concentrate line to zero (exiting Chinese offtake) and replaced it — and then some — with refined NdPr and magnets. Concentrate was $107.6M (9M'24) → $42.0M (9M'25) → 0. NdPr oxide/metal went $34.0M (9M'24) → $80.3M (9M'25) → accelerating. This is a higher-value, higher-margin, domestically-controlled mix replacing a low-value commodity export.

Production volumes:

• FY2025: REO production 50,692 MT (record, +12%); NdPr production 2,599 MT (+101%).
• Q1'26: NdPr production 917 MT (+63%); NdPr sales 1,006 MT (+117%, drawing inventory); REO production 12,983 MT (+6%).

Trend: Materials Adj. EBITDA accelerating hard (Q1'26 segment Adj. EBITDA $36.7M, +877% YoY); Magnetics scaling from breakeven to $9.6M in Q1'26. Geographic detail is not broken out in the ingested filings beyond "U.S." for Magnetics; flag as n/a — not segmented in filings.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1 2026, filed 2026-05-08)

The headline numbers and what they mean [all research-layer: filings/10-q-2026-q1.md]:

• Revenue $90.6M, +49% YoY (vs $60.8M). Plus $42.3M price-protection income (a separate line above operating costs) — so total revenue + PPA income ≈ $132.9M.
• Operating loss $(24.1)M, narrowed from $(34.8)M. Still GAAP-unprofitable at the operating line because of D&A ($32.1M, incl. $11.2M of price-protection-asset amortization), start-up costs ($5.9M ramping), and SG&A ($33.6M).
• Net loss $(8.0)M / $(0.04) per share, vs $(22.6)M / $(0.14). A 65% reduction in net loss.
• Adjusted EBITDA $36.6M, vs $(2.7)M PY — the swing to clearly positive segment cash economics is the most important number in the print.
• Adjusted Net Income $6.7M / Adjusted Diluted EPS $0.03, vs $(0.12) PY — MP crossed into adjusted profitability.
• Margins: cost of sales $74.2M on $90.6M product revenue (gross profit positive but thin pre-PPA); the PPA income is what carries the quarter to adjusted-positive.
• Balance sheet (3/31/26): cash + short-term investments $1.74B; total debt ~$1.0B ($67.5M current + $932.9M long-term, the convertible notes); PP&E $1.43B; total assets $3.84B; total stockholders' equity $1.97B; Series A convertible preferred $413.6M (DoD, 400K shares, liquidation pref $420.7M). Net cash position even mid-build.
• Cash flow: operating cash flow $(1.9)M (near-breakeven, vs $(63.2)M PY — a massive improvement); capex $(77.4)M (ramping, vs $30.5M PY) → FCF ≈ $(79.3)M. The burn is now almost entirely growth capex, not operating losses.
• Inventory $169.2M current (NdPr sold > produced, so inventory drew); receivables rose ($47.3M trade, +$32.6M working-capital use) as the DoD/customer mix matures.
• Guidance: the ingested filing carries no explicit numeric guidance table (guidance.csv empty); management's framing is the scaling of NdPr + magnet capacity toward a stated ~$650M adjusted-EBITDA goal at full ramp. Treat the $650M as a management aspiration, not a dated guide.

Unusual vs. own history: the concentrate line going to zero, the PPA income appearing, and Adjusted EBITDA flipping positive are all first-time structural events, not noise. Market reaction / "what was priced in": see Lens 8 — the stock has been a high-beta policy proxy; the DoD deal re-rated it sharply in mid-2025.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty). From the quarterly arc and public commentary:

• Tone trajectory across the last 4 quarters: Q1'25 → "ramp underway, China offtake intact"; Q2–Q3'25 → trough quarter, defensive ("we ceased shipments to China," near-term revenue hit acknowledged, downstream emphasized); Q4'25–Q1'26 → confident, vindicated ("price floor working," "first commercial magnets," "adjusted EBITDA positive"). Management's language shifted from building to delivering.
• Recurring phrases: "mine-to-magnet," "vertical integration," "supply-chain independence," "reduce reliance on Chinese rare-earth processing," "$110 floor."
• Things they stopped saying: anything framing Shenghe / China as a growth channel. The concentrate-export narrative was retired in 2025.
• Sentiment net: improving and increasingly assertive, congruent with the financial inflection. Caveat: ``, not from primary transcripts — fetch the Q1'26 call transcript to confirm before any high-conviction action.

Lens 7 · Comps

Peer set: the non-China Western rare-earth complex.

Conflict surfaced (do not silently reconcile): market-cap prints for MP ranged $10.16B (at $58.26, Jun 15), $11.35B, and $13.7B across sources within days — consistent with a high-volatility name and different snapshot dates. I am not picking one; treat MP's cap as "low-to-mid $10Bs, very price-sensitive." Trailing EV/EBITDA is not meaningful (TTM EBITDA negative); the bull case is built on a forward ~$650M EBITDA target, on which the implied forward EV/EBITDA would be roughly mid-teens only if that target is hit — see Lens 11. There is no clean trailing earnings multiple that makes MP look cheap; on P/S it is ~50x, an extreme premium to the materials industry.

Takeaway: MP is the largest and most de-risked (DoD floor) of the cohort, and it trades like it — at a steep premium to Lynas/Energy Fuels on every backward-looking metric. You are not buying value; you are buying the only Western mine-to-magnet platform with a government backstop, at a strategic-scarcity multiple.

Lens 8 · Stock-Price Catalysts (moves >5%, last ~5 years)

Pattern of what actually moves MP:

• 2020 SPAC debut (Fortress Value Acquisition Corp.) and the 2021–22 EV/rare-earth-mania run-up — retail + thematic flows.
• GM long-term magnet agreement (Dec 2021/2022) — validated the downstream pivot; positive.
• China policy / tariff headlines — MP is a high-beta proxy for U.S.–China rare-earth tension. Every escalation (export controls, the April 2025 125% Chinese retaliatory tariff) spikes it; every de-escalation deflates it.
• The July 9, 2025 DoD deal — the single largest re-rating event: a multi-billion strategic partnership, $400M equity, $110 floor, 10X facility. The stock stepped up sharply.
• Quarterly prints — matter, but secondary to policy. The Q3'25 trough loss did not break the stock because the DoD backstop had already changed the risk profile.
• Insider buying — COO Michael Rosenthal bought 10,000 shares (June 10, 2026) amid sector weakness — a mild positive signal.

What the market reacts to, ranked: (1) China/geopolitics, (2) government policy/contracts, (3) NdPr price, (4) earnings. MP trades as a geopolitical option more than as a cash-flow stock — the most important fact for sizing and timing a position.

---

Phase C — Judge people & books

Lens 9 · Management

James H. Litinsky — Founder, Chairman & CEO. The defining figure. Before MP he founded JHL Capital Group (2006), a multibillion-dollar alternative-investment firm (CEO/CIO), with roots at Fortress's Drawbridge Special Opportunities fund.

• Track record — exceptional, and quantified. A small JHL position in the distressed debt of bankrupt Molycorp led to Litinsky's consortium (JHL + QVT + Shenghe) buying the Mountain Pass mine out of bankruptcy at auction for $20.5M in June 2017. He took it public in 2020 and built it into a low-to-mid-$10B-cap national-champion platform. Turning a $20.5M distressed asset into a multi-billion strategic company — and engineering a U.S.-government equity partnership around it — is a top-decile capital-allocation and dealmaking record.
• Skin in the game — high. Litinsky is the largest individual shareholder; NEOs must hold ≥5x salary and all exceed it. Founder-owner alignment is genuine.
• Capital allocation — aggressive reinvestment, opportunistic financing. He has consistently plowed capital into vertical integration (Stage II/III, Independence, 10X) and financed it cleverly — convertible notes, the GM prepayments, government grants/45X credits, and the DoD preferred+warrant — without diluting common holders to death (the DoD took preferred + warrants, preserving common). ROE/ROIC are currently negative (build phase), so judge him on asset value created, not on accounting returns yet.
• Red flags — modest but worth naming. (1) Shenghe is both a former major customer and a major shareholder — an embedded related-party tension, now partly defused by the China exit but still a governance footnote. (2) Litinsky's hedge-fund background means he is a financier-operator, promotional and narrative-savvy; the "mine-to-magnet" framing is masterful storytelling as well as strategy. (3) The DoD deal, while transformational, makes the U.S. government a 15% owner with attendant strategic strings.
• Archetype: founder-financier, not a career metallurgist. For a capital-intensive, policy-dependent, dealmaking-heavy business at this stage, that is arguably the right archetype — the binding constraints have been capital and Washington, not metallurgy, and that is exactly where he is strongest.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst on the filings:

• Revenue recognition / the PPA income line. The $42.3M (Q1'26) / $51.0M (FY2025) "price protection agreement income" is a new, non-product revenue stream — cash from DoD for the price shortfall. It is legitimate and contractual, but it flatters both revenue and Adjusted EBITDA: strip it out and Q1'26 Adjusted EBITDA of $36.6M would be materially negative. Watch that the market does not capitalize PPA income as if it were durable product margin — it is a subsidy tied to low NdPr prices and shrinks if prices rise above $110/kg. There is also a $209.7M "price protection agreement upfront asset" on the balance sheet being amortized into D&A ($11.2M/quarter) — a sizable intangible to monitor.
• Cash flow vs. earnings. Healthy direction: Q1'26 operating cash flow $(1.9)M is better than the $(8.0)M net loss (D&A + SBC add-backs), and far better than PY. No divergence red flag — if anything, GAAP losses overstate the cash drain because they carry heavy non-cash D&A and start-up costs.
• Stock-based compensation. SBC $12.9M (Q1'26 cash-flow add-back) on a $90.6M revenue quarter is meaningful (~14% of revenue) and is a real economic cost the Adjusted figures partially normalize. Dilution is visible: shares outstanding rose to ~178.0M (Q1'26) from ~163.4M (Q1'25), partly from equity issuance and SBC vesting.
• Receivables / inventory vs. revenue. Trade receivables jumped to $47.3M (from $14.6M) and were a $32.6M working-capital use. Worth watching as customer mix shifts to DoD/large offtakers, but not yet outrunning revenue alarmingly. Inventory drew down (sales > production) — benign.
• Debt / preferred complexity. ~$1.0B convertible notes + $413.6M Series A convertible preferred (DoD) + warrants create a layered capital structure with future dilution paths. The DoD warrant strike is $30.03, well below the current price — in-the-money dilution overhang on the common.
• Goodwill/intangibles: the PPA upfront asset and capitalized development are the items to watch for impairment if NdPr economics or the 10X timeline slip.

Regulatory findings (required sub-section).

• SEC Litigation Releases: None. "No LR found for this company in the search period".
• SEC AAERs: None. "No AAER found".
• Item 3 (Legal Proceedings), FY2025 10-K: the ingested 10-K markdown did not retain a quotable Item 3 block (the extraction dropped most Item 1A/3 narrative); a $8.8M settlement of a construction-related litigation matter is referenced in Q1'26 other operating expenses — ordinary-course construction dispute, immaterial to the thesis.
• Non-SEC web sweep ("MP Materials" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement): no material federal enforcement action surfaced. The only "government" entanglement is the favorable DoD partnership.
• Net: No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and the available filing references as of 2026-06-18. The forensic watch-items are economic (PPA-income durability, SBC dilution, capital-structure complexity), not integrity red flags.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 → FY2028)

Built bottom-up from the latest actuals. All outputs ``; inputs labeled. No forecast.ts logged (watchlist/unattended rule).

Anchor (TTM/run-rate): Q1'26 revenue $90.6M (+ $42.3M PPA) → annualized product revenue ~$363M; Q1'26 Adjusted EBITDA $36.6M → ~$146M run-rate, of which a large share is PPA income tied to sub-$110 NdPr. FY2025 actuals: revenue $224.4M, Adj. EBITDA $11.4M.

Drivers: (a) NdPr volume scaling (Stage II/III ramp, 2,599 MT FY25 → higher); (b) magnet revenue ramp (Independence ~1,000 MT/yr finished, GM + others); (c) PPA income that is inversely tied to NdPr price (more income if prices stay low, less if they rise — a natural hedge on revenue but not on quality of revenue); (d) start-up costs and D&A rising with the build; (e) 10X capex (commissioning 2028) — pre-revenue drag until then; (f) dilution from converts/warrants/SBC (~178M shares rising).

EPS: GAAP EPS likely remains near breakeven-to-slightly-negative through FY2026–27 (heavy D&A + start-up + dilution), turning solidly positive only as magnets scale and 10X contributes (FY2028+). Adjusted EPS is already marginally positive ($0.03 in Q1'26) and should grind higher in the base case. I will not publish a precise EPS line — the swing factors (NdPr price, 10X timing, dilution) are too wide and no clean consensus EPS was sourceable beyond a forward P/E of ~134x implying tiny near-term EPS. n/a — not cleanly sourced for a point GAAP-EPS estimate.

The number that matters most: does cash reach the catalysts? Yes, comfortably — $1.74B cash + short-term investments vs. ~$(79)M/quarter FCF burn and a self-funding-ish operating line means MP is fully funded through the 10X build without forced dilution. This is the strongest leg of the bull case.

Lens 12 · Bull vs Bear

Bull case. MP is the only at-scale Western mine-to-magnet platform, with an irreplaceable orebody, a U.S.-government anchor customer + 15% owner + $110/kg price floor that removes the downside that has historically killed rare-earth miners, a fully-funded balance sheet ($1.74B), and a credible path to ~$650M adjusted EBITDA as NdPr and magnets scale into the 10X facility (2028+). The secular tailwind — defense, EVs, robotics/humanoids, and the West's structural drive to decouple from Chinese rare-earth processing — is enormous and policy-supported. The Q1'26 inflection to positive Adjusted EBITDA and adjusted EPS proves the model works at the unit level. Earnings surprise vector: a sharp NdPr price spike (China export curbs) would let MP earn above the floor while keeping the policy premium — convex upside.

Bear case. Three things could permanently impair or de-rate the equity: (1) Valuation. At ~134x forward earnings, ~50x sales, and trading 76–102% above its 5-year-average multiples, the stock already prices in flawless execution and a 10X facility that won't produce until 2028 — a 50% correction still might not make it cheap on backward metrics. (2) NdPr price + PPA optics. A large slug of current "EBITDA" is DoD price-protection income, not product margin — it exists because NdPr is cheap. If China eases export curbs and prices stay low, MP's product economics stay thin and the market may re-rate the PPA-juiced numbers downward; if prices rise, PPA income evaporates and the bull must rely entirely on volume + magnets delivering. Either way the "quality" of the EBITDA is questioned. (3) Execution / dilution. 10X is a large, on-time-2028-dependent build; magnet qualification with OEMs is slow; the convert+warrant+SBC stack is a real dilution overhang (DoD warrant strike $30.03, deep ITM).

Pre-mortem (18 months out, thesis broke): China de-escalated, NdPr stayed at multi-year lows, the 10X timeline slipped a year, magnet qualification at non-GM OEMs lagged, the market decided to value MP on product EBITDA ex-subsidy — and a ~$58 stock priced for perfection fell to the mid-$30s (near the DoD warrant strike), where the contractual floor on the business (not the stock) finally put a bid under it.

Are multiples too high? On any trailing basis, unambiguously yes. The question is whether the strategic scarcity + government backstop + 2028 optionality justify paying forward. Contrarian view of what the market is missing (both ways): bulls under-weight that a big chunk of today's profitability is a low-price subsidy, not a moat-driven margin; bears under-weight that the DoD floor fundamentally changes the bankruptcy-risk profile that has always made rare-earth equities un-ownable — MP is the first rare-earth miner you literally cannot be wiped out on by a Chinese price war. That asymmetry is real and rare.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Revenue concentration just moved, it didn't disappear. MP swapped ~30–80% Shenghe/China concentration for DoD + GM + one big tech offtaker concentration. If GM's EV ramp disappoints, or DoD's procurement priorities shift with an administration change, or the unnamed tech offtaker (reportedly Apple) walks, the customer base is still a handful of names. Government as customer/owner cuts both ways — political risk replaces market risk.
• The moat on the price is a subsidy, and subsidies are political. The $110/kg floor is a 10-year contract with a government — durable, but not immutable. More importantly, a floor is not a margin. It guarantees survival, not prosperity. Bulls conflate "can't go bankrupt" with "deserves 50x sales."
• The most dangerous competitor bulls underestimate isn't another miner — it's China easing up. China doesn't need to out-mine MP; it needs only to flood NdPr / loosen export controls to (a) crater the spot price (gutting MP's product economics while PPA income caps the offset) and (b) deflate the entire "decoupling" narrative premium that 80% of MP's valuation rests on. The thesis is short Chinese-supply-discipline; that's a thin reed.
• Worst capital-allocation / governance items: the Shenghe related-party history; a layered convert+preferred+warrant capital structure that dilutes common; a hedge-fund-founder CEO whose superpower is narrative + financing — which is exactly what you'd worry about if the story ever needs to be propped.
• Assumptions that must hold for $58: NdPr recovers or volumes + magnets scale enough to hit ~$650M EBITDA; 10X commissions ~2028 on budget; the decoupling premium persists; no forced dilution. If FY2027 revenue disappoints by 20–30% (bear ~$400M vs base ~$520M), the forward multiple — already ~134x — has no earnings to grow into and the stock likely halves.
• Single scenario that permanently impairs: a durable U.S.–China rare-earth détente (export controls lifted, prices normalized low) that simultaneously kills the price and the strategic premium, leaving MP a sub-scale, subsidized magnet maker valued like a commodity miner. Plausibility: moderate — it requires a geopolitical thaw that, as of mid-2026, looks unlikely but is not impossible.

Lens 14 · Management Questions (ordered by information value)

1. Strip out price-protection income: what is the product-only gross and EBITDA margin of Materials and Magnetics today, and what NdPr price do you need for each segment to stand on its own without the DoD floor?
2. What is the realistic commissioning and full-run-rate timeline for the 10X facility, and what are the two or three things most likely to slip it past 2028?
3. How much of your forward magnet capacity (Independence + 10X) is contractually committed under binding offtake versus framework/intent, and to whom, by year?
4. What is the total potential common-share dilution if the DoD warrant, the convertible preferred, and the convertible notes are all exercised/converted — i.e. fully-diluted share count at today's price?
5. On heavy rare earths (Dy/Tb): what is your sourcing plan for high-temperature magnets, and how dependent does that leave you on Chinese or other foreign heavy-REE supply?
6. If China lifts export controls and NdPr stays below $110/kg for three years, what does the business look like — and at what point does the DoD floor renegotiate or expire?
7. What is the path to GAAP profitability, and which year do you expect positive GAAP net income and positive free cash flow?
8. How concentrated is magnet revenue beyond GM — what is the second and third large OEM/defense program, and where are they in qualification?
9. What is the U.S. government's posture as a 15% owner: governance rights, board input, constraints on M&A or capital returns, and what changes with an administration change?
10. What is your capital-allocation priority once the 10X build is funded — further downstream integration, heavy-REE, buybacks, or international expansion?
11. How do you think about the durability of the "decoupling premium" in your valuation, and what would you tell an investor worried it's a policy bubble?
12. What is the status of the Shenghe relationship and shareholding now that concentrate sales have ceased — any path to them exiting the register?
13. What are realized NdPr and magnet ASPs trending, and how should we model the spread between your cost and the benchmark over the next three years?
14. What is the single largest operational risk at Mountain Pass or Independence (recovery rates, throughput, environmental/permitting) that could disrupt the volume ramp?
15. What would you most want a long-term shareholder to judge you on over the next five years — and what metric would tell you the strategy had failed?

---